A survey of IBD patients using the IBD Resource Use Questionnaire
Research type
Research Study
Full title
Resource use and costs of Inflammatory Bowel Disease in the UK: a cross-sectional survey
IRAS ID
309656
Contact name
Borislava Mihaylova
Contact email
Sponsor organisation
Queen Mary University of London
Duration of Study in the UK
2 years, 2 months, 31 days
Research summary
Inflammatory Bowel Disease (IBD), comprising Crohn’s Disease (CD) and ulcerative colitis (UC) is a chronic inflammatory disease of the gastrointestinal tract. Being a chronic disease, patients with IBD require frequent investigations, life-long medication, and surgery. Therefore, the economic burden of managing IBD for health systems, patients, and society is substantial.
Previous cost-of-illness studies in continental Europe, have estimated the mean annual healthcare costs for IBD between £5,540 and £9,090. However, to the best of our knowledge, there have been no such detailed studies undertaken within the UK National Health Service (NHS) and therefore, little is known about healthcare resource utilisation and cost in the UK for people with IBD.
To address this, we will conduct a cross-sectional survey in a large cohort of over 2000 IBD patients in the UK. A link to the online survey will be emailed or a hard copy will be provided by the research team inviting them to the study. We will collect data using a recently developed comprehensive resource use questionnaire as well as validated scales on CD and UC severity, control of their IBD, work productivity and activity impairment and quality of life. We will also collect data on their health, demographic and clinical characteristics, and lifestyle.
This study aims to be the first large UK study providing evidence on the cost as well as the cost drivers of IBD from the perspectives of NHS, the patients, and the society. Additionally, we will also aim to validate the IBD-specific resource use questionnaire so it can be used in future research.
REC name
London - South East Research Ethics Committee
REC reference
22/PR/1376
Date of REC Opinion
4 Nov 2022
REC opinion
Further Information Favourable Opinion